PMC:7546139 / 15487-15767 JSONTXT

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T86","span":{"begin":30,"end":31},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T87","span":{"begin":73,"end":81},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T88","span":{"begin":206,"end":212},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T89","span":{"begin":260,"end":268},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"Treatment with 38% SDF and/or a 5% NaF varnish therapy to reduce carious activity and promote remineralisation.33 These additional measures can support success of the NRCC approach if the carious lesion is active or there is increased risk that carious lesion activity will recur."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T75","span":{"begin":35,"end":38},"obj":"Chemical"}],"attributes":[{"id":"A75","pred":"chebi_id","subj":"T75","obj":"http://purl.obolibrary.org/obo/CHEBI_28741"}],"text":"Treatment with 38% SDF and/or a 5% NaF varnish therapy to reduce carious activity and promote remineralisation.33 These additional measures can support success of the NRCC approach if the carious lesion is active or there is increased risk that carious lesion activity will recur."}

{"project":"LitCovid-sentences","denotations":[{"id":"T158","span":{"begin":0,"end":280},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Treatment with 38% SDF and/or a 5% NaF varnish therapy to reduce carious activity and promote remineralisation.33 These additional measures can support success of the NRCC approach if the carious lesion is active or there is increased risk that carious lesion activity will recur."}

{"project":"LitCovid-PubTator","denotations":[{"id":"138","span":{"begin":35,"end":38},"obj":"Gene"},{"id":"139","span":{"begin":19,"end":22},"obj":"Chemical"},{"id":"140","span":{"begin":188,"end":202},"obj":"Disease"},{"id":"141","span":{"begin":245,"end":259},"obj":"Disease"}],"attributes":[{"id":"A138","pred":"tao:has_database_id","subj":"138","obj":"Gene:3576"},{"id":"A139","pred":"tao:has_database_id","subj":"139","obj":"MESH:C024633"},{"id":"A140","pred":"tao:has_database_id","subj":"140","obj":"MESH:D003731"},{"id":"A141","pred":"tao:has_database_id","subj":"141","obj":"MESH:D003731"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Treatment with 38% SDF and/or a 5% NaF varnish therapy to reduce carious activity and promote remineralisation.33 These additional measures can support success of the NRCC approach if the carious lesion is active or there is increased risk that carious lesion activity will recur."}